Basic information

  • Product Name:Bentazepam
  • CasNo.:29462-18-8
  • MF:C17H16 N2 O S
  • MW:296.393

Physical and Chemical Properties

  • Purity:99%
  • Boiling Point:249.5°C
  • Packing:
  • Throughput:

Product Details

CasNo: 29462-18-8

MF: C17H16 N2 O S

Quality Factory Supply 29462-18-8 with Efficient Transportation, Buy High Grade Bentazepam 

  • Molecular Formula:C17H16 N2 O S
  • Molecular Weight:296.393
  • Vapor Pressure:2E-11mmHg at 25°C 
  • Melting Point:249.5°C 
  • Refractive Index:1.7400 (estimate) 
  • Boiling Point:532.6°C at 760 mmHg 
  • PKA:13.24±0.40(Predicted) 
  • Flash Point:275.9°C 
  • PSA:69.70000 
  • Density:1.38g/cm3 
  • LogP:2.99000 

Bentazepam(Cas 29462-18-8) Usage


Bentazepam is a thienodiazepine which is a benzodiazepine analog. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Peak plasma rates are achieved in around 2,5 hours after oral administration. The elimination half-life is between approximately 2–4 hours.

Therapeutic Function

Anticonvulsant, Tranquilizer

Safety Profile

Moderately toxic by ingestion andintraperitoneal routes. When heated to decomposition itemits toxic fumes of SOx and NOx.

Supplier Dorne chemical technology co. LTD is a comprehensive chemical enterprise integrating r&d, production and sales. It is a leading manufacturer and supplier of chemical products in China.We develop, produce and market high quality pharmaceuticals, intermediates, specialty chemicals and OLED intermediates, as well as other fine chemicals.Relying on the laboratory and taking the factory as the base, the company has the whole process ability of fine chemical product research and development, production and processing, testing and packaging to export.


29462-18-8 Relevant articles

Bentazepam versus cloracepate in the treatment of anxiety disorders

A. Higueras 1, J.J. Sanmatias 1, E. Padial 1, J. Garrido 2, F.J. Otero 2, J. Velasco 2

, Current Therapeutic Research Volume 52, Issue 1, July 1992, Pages 46-52

A 6-week, parallel, randomized, open-label study was conducted to evaluate the effects of bentazepam 75 mg/day versus those of clorazepate 30 mg/day in 50 patients with anxiety disorders. Both drugs reduced anxiety as measured by the Hamilton Anxiety Scale (HAS) and the State-Trait Anxiety Inventory (STAI). The mean HAS and STAI scores at weeks 1, 3, and 6 in patients receiving bentazepam were significantly lower than those of patients receiving clorazepate. Patients taking bentazepam also exhibited improved performance on cognitive tests (Digit-Symbol Substitution Test and Digit Span).

A comparison of bentazepam versus ketazolam in anxiety disorders diagnosed according to DSM-III-R

V Pedreira, J Blanco, MV Rodriguez, JF Hierro

, Current Therapeutic Research Volume 55, Issue 3, March 1994, Pages 348-355

Bentazepam (BTZ), 75 mg/day, and ketazolam (KZ), 30 mg/day, were compared in a parallel, randomized, non-blind study conducted with 40 outpatients diagnosed with anxiety disorders according to the Diagnostic and Statistical Manual of Mental Disorders, revised third edition. After a 1-week washout period to anxiolytic drugs, patients were assigned to either BTZ (n = 20) or KZ (n = 20) treatment. Both the Hamilton Anxiety Rating Scale (HARS) and State subscale from the State-Trait Anxiety Inventory of Spielberger (STAI-S) were administered at baseline and at weeks 1, 3, and 6 of treatment.

29462-18-8 Upstream products

  • 623-33-6

    glycine ethyl ester hydrochloride

  • 43215-25-4


  • 29462-27-9


  • 41042-86-8

    glycine 3-benzoyl-4,5,6,7-tetrahydro-benzo[b]thiophen-2-ylamide

29462-18-8 Downstream products

  • 40054-65-7


  • 50509-63-2


  • 50509-64-3


  • 40054-52-2

    5-phenyl-1,3,6,7,8,9-hexahydro-benzo[4,5]thieno[2,3-e][1,4]diazepin-2-one hydrazone